Mednet Logo
HomeRadiation OncologyQuestion

What is your treatment paradigm for rectal cancer in the setting of COVID-19?

2
4 Answers
Mednet Member
Mednet Member
Radiation Oncology · Henry Ford Health System

We haven't changed our standard recommendation: short course radiation -> 3-4 months of FOLFOX. In a very timely manner, the RAPIDO ASCO abstract was released here in May. It showed that the patients who received short course radiation -> FOLFOX had improved pCR, less disease related treatment failu...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Radiation Oncology · Fox Chase Cancer Center

This is a difficult scenario where none of us has enough information to make a completely informed decision. However, all of the modeling that I've seen suggests that personal contact and exposure are the primary drivers of the pandemic. To that end, we've tried to minimize this as much as possible....

Register or Sign In to see full answer

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

Discuss every case in MDC and favor neoadjuvant chemo and short course RT unless concern about circumferential margin, low lying lesion with plan to possible assess for non surgical approach or side wall nodes.

Register or Sign In to see full answer

Mednet Member
Mednet Member
Radiation Oncology · Dartmouth-Hitchcock Medical Center/Norris Cotton Cancer Center

I've been offering and administering short course more routinely but have noted that patients have significant radiation proctitis (tenesmus, frequency, sometimes bleeding) for at least 2-3 weeks post treatment, if not longer.

Other than Imodium and low residue diet, do you recommend additional ther...

Register or Sign In to see full answer